TTF-1 甲状腺转录因子1（克隆号SPT24）

广州健仑生物科技有限公司

TTF-1表达于甲状腺腺上皮和肺上皮细胞中。肺肿瘤研究发现，大多数肺小细胞癌、肺腺癌、小部分未分化大细胞肺癌和非典型类癌、少数典型类癌表达TTF-1，而肺鳞癌不表达。在甲状腺乳头状腺癌中TTF-1也呈阳性，而TTF-1在其它组织均阴性表达。因此，TTF-1可用来研究肺腺癌和鳞癌，并有助于肺腺癌转移至肺外部位的研究。

我司还提供其它进口或国产试剂盒：登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

欢迎咨询

欢迎咨询

TTF-1 甲状腺转录因子1（克隆号SPT24）

【产品介绍】

细胞定位：细胞核/细胞浆

克隆号：SPT24

同型：IgG

适用组织：石蜡/冰冻

阳性对照：甲状腺乳头瘤/肺腺癌/肝癌

抗原修复：热修复（EDTA）

抗体孵育时间：30-60min

TTF-1

想了解更多的产品及服务请扫描下方二维码：

【公司名称】 广州健仑生物科技有限公司
【市场部】     欧

【】 
【腾讯  】 
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室

一旦获得被研究人员称之为“抗原抗体者”(因为其具有攻击和摧毁癌细胞的能力)的细胞，t细胞被输回到病人体内进行繁殖并攻击癌细胞。此外因为CAR抗原可以接受控制，研究人员让细胞快速繁殖，宛如可以大规模杀死癌细胞的“抗原抗体者细胞*”。事实上试验显示，一个植入细胞可以在病人身上繁殖出1万个新细胞。
报道称，到目前为止，参与试验的19名患者症状得到缓解，其中15名患者仅使用了这一种疗法，包括一名9岁儿童，他是两年前*个接受CTL019疗法的病人。所有接受CTL019细胞的患者在接受细胞输入几天后都出现了细胞因子释放综合征，这是经过修改的细胞在患者体内繁殖和攻击肿瘤细胞的标记，病人症状轻重各有不同，表现为流感、高热、抗原抗体、肌肉疼痛、低血压和呼吸困难等，但经过配合治疗zui后这些症状在所抗原抗体人身上都会消失。与此同时，那些ALL病症*消除的患者，他们体内同样带有CD19蛋白的非肿瘤正常B细胞也随着肿瘤被一起清除了。研究人员指出，接受CTL019疗法后正常B细胞持续缺失说明基因改良T细胞在持续活动，相信它们可以起到类似于预防肿瘤复发的长期疫苗的作用。

Once cells are known by researchers as "antigen-antibodies" (because of their ability to attack and destroy cancer cells), the t-cells are returned to the patient's body to multiply and attack the cancer cells. In addition, because CAR antigens are under control, researchers are able to multiply cells quickly, just like the "army of antigen-antibody cells" that kill cancer cells on a large scale. In fact, experiments show that one implanted cell produces 10,000 new cells in the patient.
To date, the 19 patients who participated in the trial were relieved of symptoms, 15 of whom used this therapy alone, including a 9-year-old child who was the first patient to receive CTL019 therapy two years earlier. All patients who received CTL019 cells developed cytokine release syndrome a few days after receiving the cell input, a marker of a modified cell that multiplied and attacked the tumor cells in the patient. The patient's symptoms varied in severity, manifested as flu, Fever, antigen and antibody, muscle pain, hypotension and dyspnea, but after the treatment of these symptoms in the final anti-human antibodies will disappear. In the meantime, patients with complete elimination of ALL disease also have non-tumor-normal B cells that also carry CD19 protein in their body cleared with the tumor. The researchers pointed out that the continued absence of normal B cells following CTL019 therapy suggests that the genetically modified T cells are continuously active, believing they can act as long-term vaccines that prevent tumor recurrence.